US 12,252,505 B2
SIRT1 activating compounds
David A. Sinclair, Chestnut Hill, MA (US); and Conrad Rinaldi, Cambridge, MA (US)
Assigned to President and Fellows of Harvard College, Cambridge, MA (US)
Appl. No. 17/284,691
Filed by President and Fellows of Harvard College, Cambridge, MA (US)
PCT Filed Oct. 16, 2019, PCT No. PCT/US2019/056487
§ 371(c)(1), (2) Date Apr. 12, 2021,
PCT Pub. No. WO2020/081654, PCT Pub. Date Apr. 23, 2020.
Claims priority of provisional application 62/746,251, filed on Oct. 16, 2018.
Prior Publication US 2021/0371446 A1, Dec. 2, 2021
Int. Cl. C07H 19/048 (2006.01); A61K 45/06 (2006.01); C07D 213/80 (2006.01); C07D 213/82 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 409/12 (2006.01)
CPC C07H 19/048 (2013.01) [A61K 45/06 (2013.01); C07D 213/80 (2013.01); C07D 213/82 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 409/12 (2013.01)] 19 Claims
 
1. A compound having a structure of Formula I, II or III, or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
wherein
Z1, Z2, Z3, and Z4 are each independently selected from —OC(O)-L1-R1, —OC(NR6)-L1-R1, and

OG Complex Work Unit Chemistry
if the compound has the structure of Formula I, L1 is a linker group selected from

OG Complex Work Unit Chemistry
if the compound has the structure of Formula II or III, L′ is absent or a linker group selected from

OG Complex Work Unit Chemistry
R1 is

OG Complex Work Unit Chemistry
R2 is independently selected from H, optionally substituted alkyl, heteroalkyl, aralkyl, and heteroaralkyl;
R3 is selected from H, optionally substituted alkyl, heteroalkyl, aryl, and heteroaryl;
R4 is selected from H, optionally substituted alkyl, heteroalkyl, alkenyl, aryl, and heteroaryl;
R6 is selected from H and alkyl; and
m, n, p, q are each independently an integer selected from 1 to 10.